(Q33518011)

27 July 2017

title

Hepatic profile analyses of tipranavir in Phase II and III clinical trials (English)

1 reference

27 July 2017

main subject

phase II clinical trial

0 references

6

Jürgen Rockstroh

1 reference

27 July 2017

5

Stanislas Pol

1 reference

27 July 2017

2

Mark S Sulkowski

1 reference

27 July 2017

Jaromir Mikl

1

1 reference

27 July 2017

Yves Benhamou

3

1 reference

27 July 2017

Douglas Dieterich

4

1 reference

27 July 2017

Patrick A Robinson

7

1 reference

27 July 2017

Mithun Ranga

8

1 reference

27 July 2017

Jerry O Stern

9

1 reference

27 July 2017

publication date

14 December 2009

1 reference

27 July 2017

published in

BMC Infectious Diseases

1 reference

27 July 2017

volume

9

1 reference

27 July 2017

page(s)

203

1 reference

Creative Commons Attribution 2.0 Generic

27 July 2017

copyright license

start time

1 December 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803791

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803791

Sex differences in pharmacokinetics and toxicity of antiretroviral therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803791

Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803791

Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803791

Liver enzymes elevation after HAART in HIV-HCV co-infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803791

A trial of three antiretroviral regimens in HIV-1-infected children

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803791

Interaction between HIV-1 and HCV infections: towards a new entity?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803791

Liver toxicity in epidemiological cohorts

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803791

Looking beyond highly active antiretroviral therapy: drug-related hepatotoxicity in patients with human immunodeficiency virus infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803791

Hepatitis C and progression of HIV disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803791

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803791

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803791

Hepatitis C and HIV infection: biological, clinical, and therapeutic implications

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803791

Combination antiretroviral therapy and recent declines in AIDS incidence and mortality

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803791

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803791

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803791

Rates of spontaneous mutation among RNA viruses

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803791

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-9-203

Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-9-203

Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-9-203

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-9-203

Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-9-203

Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-9-203

Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-9-203

Influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-9-203

Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-9-203

Perceived adverse effects of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-9-203

Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2803791

Efficacy And Safety of Three Doses of Tipranavir Boosted with Ritonavir in Treatment-Experienced HIV Type 1-Infected Patients

31 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-9-203

Ritonavir-Boosted Tipranavir Demonstrates Superior Efficacy to Ritonavir-Boosted Protease Inhibitors in Treatment-Experienced HIV-Infected Patients: 24-Week Results of the RESIST-2 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-9-203

Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002

21 January 2018

1 reference

12 December 2020

Hepatotoxicity of antiretrovirals: incidence, mechanisms and management

1 reference

12 December 2020

Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial

1 reference

12 December 2020

Hepatotoxicity after introduction of highly active antiretroviral therapy

1 reference

12 December 2020

Antiretroviral-associated Hepatotoxicity

1 reference

12 December 2020

Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2334-9-203

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference

27 July 2017

1 reference